Realistic expectations based on research evidence: Berberine: Meta-analyses show average weight loss of 1-3 pounds over 12 weeks in people with metabolic dysfunction 41 Ye, Y
Semaglutide is a glucagon-like peptide-1 agonist that works on the GLP-1 receptors in the body to reduce appetite by delaying gastric emptying
Moreover, intensive glycemic control itself has been linked with weight gain (51)
Its the top choice for experiments designed to crush insulin resistance, reverse fatty liver (NAFLD), or lower the inflammatory markers tied to visceral obesity
Patients should avoid skipping meals, as this increases the risk of hypoglycaemia
Initial dosing in general terms In general, initial dosing tends to start at the lower end of an established range to assess tolerability, with any adjustment directed by the provider based on response and side-effect profile